TY - JOUR
T1 - Changes in immune cell counts and interleukin (IL)-1β production in humans after a somnogenically active growth hormone-releasing hormone (GHRH) administration
AU - Marshall, Lisa
AU - Perras, Boris
AU - Fehm, Horst L.
AU - Born, Jan
N1 - Funding Information:
We are very grateful to Nicole Boes and Thorsten Spielvogel for data collection and to Steffanie Baxmann, Ann-Kristin Jürs, and Anja Otterbein for further technical assistance. This study was supported by a grant from the Deutsche Forschungsgemeinschaft to H.L.F. and J.B.
PY - 2001
Y1 - 2001
N2 - Growth hormone-releasing hormone (GHRH) has been shown to enhance slow-wave sleep (SWS) and non-rapid eye movement sleep in animals and humans. In animals the somnogenic effect of interleukin (IL)-1β appears to be mediated by GHRH. Neuroimmunological interactions in sleep are most frequently studied in humans by sleep deprivation or by cytokine administration. The present study, in contrast, investigates in humans the effect of enhanced sleep through GHRH administration on selected immune parameters. Results reveal that a single intravenous bolus of 50 μg GHRH which enhanced SWS stage 4 in the first half of the night suppressed circulating suppressor T cell (CD3+/CD8+) numbers, with a similar tendency for B cells (CD19+) and suppressed mitogen-stimulated IL-β production. When the same amount of GHRH was administered distributed across five repetitive boluses of 10 μg GHRH within 1 h, neither corresponding sleep nor immune parameters were changed significantly compared to placebo. These data suggest that GHRH can modulate immune functions through brain mechanisms which are also involved in the regulation of sleep.
AB - Growth hormone-releasing hormone (GHRH) has been shown to enhance slow-wave sleep (SWS) and non-rapid eye movement sleep in animals and humans. In animals the somnogenic effect of interleukin (IL)-1β appears to be mediated by GHRH. Neuroimmunological interactions in sleep are most frequently studied in humans by sleep deprivation or by cytokine administration. The present study, in contrast, investigates in humans the effect of enhanced sleep through GHRH administration on selected immune parameters. Results reveal that a single intravenous bolus of 50 μg GHRH which enhanced SWS stage 4 in the first half of the night suppressed circulating suppressor T cell (CD3+/CD8+) numbers, with a similar tendency for B cells (CD19+) and suppressed mitogen-stimulated IL-β production. When the same amount of GHRH was administered distributed across five repetitive boluses of 10 μg GHRH within 1 h, neither corresponding sleep nor immune parameters were changed significantly compared to placebo. These data suggest that GHRH can modulate immune functions through brain mechanisms which are also involved in the regulation of sleep.
UR - http://www.scopus.com/inward/record.url?scp=0035174956&partnerID=8YFLogxK
U2 - 10.1006/brbi.2000.0594
DO - 10.1006/brbi.2000.0594
M3 - Journal articles
AN - SCOPUS:0035174956
SN - 0889-1591
VL - 15
SP - 227
EP - 234
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
IS - 3
ER -
